Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ABT-652 · 1 trial · 1 indication
Subject reported pain intensity measured by Visual Analog Scale (0-100)
| Arm | Type | Description |
|---|---|---|
| ABT-652 high dose | EXPERIMENTAL | ABT-652 capsules- twice daily for 8 weeks. The dose of ABT-652 will depend on the Arm. |
| ABT-652 low dose | EXPERIMENTAL | ABT-652 capsules - twice daily for 8 weeks. The dose ABT-652 will depend on the Arm |
| Naproxen | ACTIVE_COMPARATOR | Naproxen capsules- twice daily for 8 weeks |
| Placebo | PLACEBO_COMPARATOR | Placebo capsules- twice daily for 8 weeks |
| Name | Type | Description |
|---|---|---|
| ABT-652 | DRUG | ABT-652 capsules - twice daily for 8 weeks. The dose of ABT-652 will depend on the Arm |
| Placebo | DRUG | Placebo capsules - twice daily for 8 weeks |
| Naproxen | DRUG | Naproxen capsules - twice daily for 8 weeks |
Inclusion Criteria * History of OA of the knee joint and meeting American College of Rheumatology (ACR) Clinical and Radiographic criteria, * Pain score as required by the protocol at Screening and Baseline * Willing to washout of analgesics and to follow treatment plan, visit schedules and study p...
ABT-652 is an investigational small molecule being developed for osteoarthritis of the knee. It is intended to treat pain associated with this condition. The drug is currently in Phase 2 clinical development and has not been approved by regulatory authorities.
ABT-652 is being developed by AbbVie Inc., a biopharmaceutical company traded on the New York Stock Exchange under the ticker ABBV. The company is conducting clinical trials to evaluate the drug's safety and efficacy for osteoarthritis of the knee.
ABT-652 is in Phase 2 clinical development. It is an investigational drug, meaning it has not been approved for commercial use. The drug is being studied for its potential to treat pain associated with osteoarthritis of the knee.
ABT-652 has one completed Phase 2 clinical trial, identified as NCT01207115. This study enrolled 322 adults with osteoarthritis pain of the knee and was conducted in the United States, Australia, Canada, Chile, and Puerto Rico. The trial was randomized, double-blind, and placebo-controlled.
No alternative names for ABT-652 have been reported. The drug is known only by its code name ABT-652 and is being developed by AbbVie Inc. for the treatment of osteoarthritis of the knee.